Soft tissue sarcoma is metastatic if it has spread to areas in the body away from the location of the original tumor. Soft tissue sarcoma may spread through the bloodstream or lymphatic system to ...

Soft tissue sarcoma (STS) is a type of cancer that develops in soft tissues, such as deep skin tissues, muscle, fat, and blood vessels. STS can occur in any part of the body, including the abdomen.

Soft tissue sarcomas are a group of rare cancers that can occur in almost any part of the body and develop in tissues like muscle, fat, and nerves. The most common types are leiomyosarcoma, ...

Causes of Soft Tissue Sarcoma:The exact soft tissue sarcoma causes remain unclear, but several risk factors have been identified. These include a family history of inherited conditions such as ...

Soft tissue sarcomas are rare solid tumors that are being increasingly classified and treated by subtype. Approximately 12,020 people will be diagnosed with a soft tissue sarcoma in the United States ...

Soft tissue sarcomas are cancers that develop in your body’s soft tissues like muscle, fat, tendons, or cartilage. Your legs are the most common place they develop. The American Cancer Society ...

Radiotherapy was associated with an 8.1-fold increased risk of developing a thoracic soft tissue sarcoma in one cohort (95% CI 1.1-60.4, P=0.0052) and 3.0-fold elevated risk in the other (95% CI 2.4-3 ...

Alveolar soft part sarcoma (ASPS) is a rare soft-tissue sarcoma with a poor prognosis and no established therapy. Recently, encouraging responses to immune checkpoint inhibitors have been reported. We ...

Against the backdrop of a case report, pembrolizumab was investigated as immunotherapy for undifferentiated pleomorphic soft tissue sarcoma. Noting that immunotherapy for soft tissue sarcoma (STS) has ...

Extraskeletal osteosarcoma is a rare and aggressive malignant tumour arising in soft tissues, distinguished by its production of osteoid without any direct attachment to the skeleton. Although it ...

Anlotinib combined with chemotherapy showed a 30.8% ORR and 82.7% DCR in advanced STS patients, indicating promising efficacy ...